Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177624 | 0.86 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL419648 | 0.83 | LPL (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4425474 | 0.81 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30622816 | 0.81 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL822504 | 0.80 | HIF1A (0.46) | LPLLIPGCA1CA2CA9 | |
| Ammonia Solution, Strong SCHEMBL28537357 | 0.80 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18125282 | 0.80 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1284346 | 0.80 | CA1 (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL581686 | 0.79 | LPL (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12496719 | 0.79 | LPL (0.51) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531698-B | Fused bicyclic heteroaryl derivatives having activity as PHD inhibitors | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| CN-111093666-A | 1, 8-naphthyridinone compounds and uses thereof | 诺维逊生物股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10287286-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20180072714-A1 | Novel Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3271357-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016148306-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-22 | — | — | WO | disclosed |
| EP-2791120-B1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-02-24 | — | — | EP | disclosed |
| US-9115121-B2 | 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072714-A1 | Novel Compounds | F12, HAX1, C1S | LPL 3497/4885LIPG 3763/4885CA1 2870/4885 |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | LPL 4843/4885LIPG 3939/4885CA1 4791/4885 |
| US-10287286-B2 | Compounds | F12, C1S, F3 | LPL 3465/4885LIPG 4316/4885CA1 1989/4885 |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | ALK, HRH3, HRH4 | LPL 4807/4885LIPG 4874/4885CA1 2563/4885 |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | LPL 4843/4885LIPG 3939/4885CA1 4791/4885 |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | LPL 4843/4885LIPG 3939/4885CA1 4791/4885 |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | LPL 3246/4885LIPG 2994/4885CA1 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.